Scholar Rock Holding Corporation
$48.13-$2.24 (-4.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $5.4B
- Revenue
- $0.00
- ROCE
- -107.5%
Price chart
Technical chartScreen technicals →+26.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +16.4%
- 3M
- -12.9%
- 6M
- -0.5%
- 1Y
- +26.6%
- 5Y
- Hidden
- This period includes a one-day price step on 7 Oct 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$2.24 (-4.4%) from $50 to $48 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in SRRK, bought on each weekday since 2021.
News & filings
What Scholar Rock Holding filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 378 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 6.95 times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
Read moreShow less
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 108.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $5.4B
- P/B
- 22.1x
- 52-week high
- $60.04
- 52-week low
- $38.02
Profitability
- ROE
- -154.0%
- ROCE
- -107.5%
- ROIC
- -949.4%
- ROA
- -93.5%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 53.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$300.6M
Solvency
- Current ratio
- 6.95
- Debt / Equity
- 0.44
- Debt / Assets
- 0.27
- CFO / Net profit
- 0.79
- Cash / Market cap
- 6.8%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $33.2M | -$134.5M |
| FY2023 | $0.00 | -$165.8M |
| FY2024 | $0.00 | -$246.3M |
| FY2025 | $0.00 | -$377.9M |
Cash flows
FY2025: -$300.0M from operations, -$300.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$132.7M | -$133.8M |
| FY2023 | -$145.2M | -$145.3M |
| FY2024 | -$200.9M | -$201.0M |
| FY2025 | -$300.0M | -$300.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$369.4M
- Net profit
- -$377.9M
- Cash from operations
- -$300.0M
- Free cash flow
- -$300.6M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$369.4M | -$377.9M | -$300.6M | -154.0% | — | +53.5% |
Monthly returns
Month-by-month returns of SRRK across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $404.3M |
| Current assets | $385.1M |
| Non-current assets | $19.1M |
| Liabilities | $158.8M |
| Current liabilities | $55.4M |
| Non-current liabilities | $103.4M |
| Equity | $245.5M |
| Paid-in capital | $1.5B |
| Retained earnings | -$1.3B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SRRK highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Scholar Rock Holding Corporation, Cogent Biosciences, Inc., CRISPR Therapeutics AG.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Scholar Rock Holding CorporationSRRKthis company | $5.4B | — | 22.1x | -154.0% | — |
| Rhythm Pharmaceuticals, Inc.RYTM | $6.0B | — | 22.3x | -74.8% | — |
| PACS Group, Inc.PACS | $5.9B | 31.0x | 6.3x | 20.2% | 25.0x |
| Mirum Pharmaceuticals, Inc.MIRM | $5.6B | -241.4x | 17.9x | -7.4% | 329.1x |
| Cogent Biosciences, Inc.COGT | $5.6B | -17.0x | 10.2x | -60.1% | -17.2x |
| Liquidia CorporationLQDA | $5.6B | -80.7x | 124.3x | -154.0% | -128.8x |
| CRISPR Therapeutics AGCRSP | $5.5B | — | 2.9x | -30.3% | — |
| Xenon Pharmaceuticals Inc.XENE | $5.1B | -14.8x | 8.8x | -59.5% | -13.3x |
| CG Oncology, Inc.CGON | $4.9B | -30.7x | 6.6x | -21.4% | -26.0x |
| Peer median | — | -23.9x | 9.5x | -44.9% | -15.3x |
Year-to-date ROI
SRRK since 1 January, against earlier years.
Historical volatility
SRRK's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -404.9% |
| FY2023 | — |
| FY2024 | — |
| FY2025 | — |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $384.6M |
| Research and developmentResearch And Development | $208.4M |
| Selling, general and administrativeSelling General And Administration | $176.2M |
| Total expensesTotal Expenses | $384.6M |
| Operating incomeOperating Income | -$384.6M |
| Interest and other | |
| Pretax incomePretax Income | -$377.9M |
| Tax | |
| Net incomeNet Income | -$377.9M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $404.3M |
| Current assetsCurrent Assets | $385.1M |
| Non-current assetsTotal Non Current Assets | $19.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $158.8M |
| Current liabilitiesCurrent Liabilities | $55.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $103.4M |
| EquityTotal Equity Gross Minority Interest | $245.5M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$300.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$300.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$377.9M |
| Depreciation and amortisationDepreciation And Amortization | $1.7M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.7M |
| Amortization of securitiesAmortization Of Securities | -$4.0M |
| Stock-based compensationStock Based Compensation | $75.6M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Change in working capitalChange In Working Capital | -$1.1M |
| Other non-cash itemsOther Non Cash Items | $5.7M |
| Investing cash flowInvesting Cash Flow | $218.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $218.7M |
| Capital expenditureCapital Expenditure | -$600.0k |
| Purchase of PP&EPurchase Of PPE | -$600.0k |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$600.0k |
| Purchase of investmentsPurchase Of Investment | -$98.0M |
| Sale of investmentsSale Of Investment | $317.3M |
| Net investment purchases and salesNet Investment Purchase And Sale | $219.3M |
| Financing cash flowFinancing Cash Flow | $228.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $228.4M |
| Debt issuedIssuance Of Debt | $74.7M |
| Debt repaidRepayment Of Debt | -$25.5M |
| Net debt issuedNet Issuance Payments Of Debt | $49.1M |
| Long-term debt issuedLong Term Debt Issuance | $74.7M |
| Long-term debt repaidLong Term Debt Payments | -$25.5M |
| Net long-term debt issuedNet Long Term Debt Issuance | $49.1M |
| Shares issuedIssuance Of Capital Stock | $91.7M |
| Common stock issuedCommon Stock Issuance | $91.7M |
| Net common stock issuedNet Common Stock Issuance | $91.7M |
| Stock options exercisedProceeds From Stock Option Exercised | $87.6M |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | $147.1M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 0.0% |
| Cash at the start of the yearBeginning Cash Position | $180.3M |
| Cash at the end of the yearEnd Cash Position | $327.3M |
| Free cash flowFree Cash Flow | -$300.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Scholar Rock Holding Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read